immatics biotechnologies GmbH - Asset Resilience Ratio
immatics biotechnologies GmbH (IMTXW) has an Asset Resilience Ratio of 46.89% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how immatics biotechnologies GmbH's Asset Resilience Ratio has changed over time. See immatics biotechnologies GmbH (IMTXW) flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down immatics biotechnologies GmbH's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IMTXW market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $300.91 Million | 46.89% |
| Total Liquid Assets | $300.91 Million | 46.89% |
Asset Resilience Insights
- Very High Liquidity: immatics biotechnologies GmbH maintains exceptional liquid asset reserves at 46.89% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
immatics biotechnologies GmbH Industry Peers by Asset Resilience Ratio
Compare immatics biotechnologies GmbH's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for immatics biotechnologies GmbH (2018–2024)
The table below shows the annual Asset Resilience Ratio data for immatics biotechnologies GmbH.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 52.82% | $367.70 Million | $696.15 Million | +12.15pp |
| 2023-12-31 | 40.67% | $207.42 Million | $509.96 Million | -11.72pp |
| 2022-12-31 | 52.40% | $213.69 Million | $407.82 Million | +45.46pp |
| 2021-12-31 | 6.94% | $12.12 Million | $174.65 Million | -2.66pp |
| 2020-12-31 | 9.60% | $24.45 Million | $254.65 Million | -2.33pp |
| 2019-12-31 | 11.93% | $16.02 Million | $134.28 Million | -9.43pp |
| 2018-12-31 | 21.37% | $13.10 Million | $61.32 Million | -- |
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more